Trial Profile
A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 Oct 2018 Status changed from recruiting to completed.
- 27 Apr 2017 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 27 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.